News
MedPage Today on MSN7h
Durable Survival Outcomes in Advanced Melanoma With Neoadjuvant Dual ImmunotherapyParticipants received 480 mg of nivolumab and 160 mg of relatlimab intravenously once every 4 weeks for two cycles before ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback